Iranian Journal of Pathology

Current Issue

By Issue

By Author

By Subject

Author Index

Keyword Index

About Journal

Aims and Scope

Editorial Board

Publication Ethics

Indexing and Abstracting

Related Links

FAQ

News

Open Access Policy

Peer Review Process

Guidelines for Reviewers

Pre-Cancerous Lesions in the Oral and Maxillofacial Region: A Literature Review with Special Focus on Etiopathogenesis

Document Type : Review Article

Author

Dental Research Center, Dept. of Oral Pathology, Dental Faculty, Hamadan University, Hamadan, Iran

Abstract

Many types of cancers develop in the oral and maxillofacial region. Squamous cell carcinoma is the most common cancer and constitutes over 90 percent of these tumors. Malignant transformation is a genetic process, which later makes a phenotyping change at the cellular level. Some cancers such as oral squamous cell carcinomas (OSCCs) develop from pre-malignant lesions and conditions. Despite advances in the treatment of OSCC, the 5-year survival rate remains approximately 50% due to inability of early detection of OSCC and precursor lesions. Early detection of oral cancer, especially in the premalignant stage, can decrease mortality and morbidity significantly. This article reviews some clinical, histopathological features and etiopathogenesis of pre-cancerous lesions of the oral cavity and skin of face and lip vermilion. A relevant English literature search in Pubmed, Science Direct, and Google Scholar was performed from 1930 to 2015. Full text of 191 articles met the specific inclusion criteria for this review.

Keywords

References
  1. Epstein JB, Zhang L, Rosin M. Advances in the diagnosis of oral premalignant and malignant lesions. J Can Dent Assoc 2002; 68(10):617-21.
  2. Silverman S Jr., Gorsky M, Lozada F. Oral leukoplakia and malignant transformation. A follow-up study of 257 patients. Cancer 1984;53(3):563-8.
  3. Lippman SM, Hong WK. Molecular markers of the risk of oral cancer. N Engl J Med 2001;344(17):1323-6.
  4. van der Waal I. Potentially malignant disorders of the oral and oropharyngeal mucosa; terminology, classification and present concepts of management. Oral Oncol 2009;45(4-5):317-23.
  5. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002.CA Cancer J Clin 2005;55(2):74-108.
  6. Myers JN, Elkins T, Roberts D, Byers RM. Squamous cell carcinoma of the tongue in young adults: increasing incidence and factors that predict treatment outcomes. Otolaryngol Head and Neck Surg 2000;122(1):44-51.
  7. Rhodus NL. Oral cancer and precancer: improving outcomes. Compend Contin Educ Dent 2009;30(8):486-8, 90-4, 96-8 passim; quiz 504, 20.
  8. Natarajan E, Eisenberg E. Contemporary concepts in the diagnosis of oral cancer and precancer. Dent Clin North Am 2011;55(1):63-88.
  9. Chen JK, Katz RV, Krutchkoff DJ. Intraoral squamous cell carcinoma. Epidemiologic patterns in Connecticut from 1935 to 1985. Cancer 1990;66(6):1288-96.
  10. Picascia DD, Robinson JK. Actinic cheilitis: a review of the etiology, differential diagnosis, and treatment. J Am Acad Dermatol 1987;17(2 Pt 1):255-64.
  11. Maserejian NN, Joshipura KJ, Rosner BA, Giovannucci E, Zavras AI. Prospective study of alcohol consumption and risk of oral premalignant lesions in men. Cancer Epidemiol Biomarkers Prev 2006;15(4):774-81.
  12. Ahlbom HE. Simple achlorhydric anaemia, plummer-vinson syndrome, and carcinoma of the mouth, pharynx, and oesophagus in women: observations at Radiumhemmet, Stockholm. Br Med J 1936;2 (3945):331-3.
  13. Akhter M, Ali L, Hassan Z, Khan I. Association of human papilloma virus infection and oral squamous cell carcinoma in Bangladesh. J Health, Popul Nutr 2013;31(1):65-9.
  14. Mao L, Lee JS, Fan YH, Ro JY, Batsakis JG, Lippman S. Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nat Med 1996;2(6):682-5.
  15. Rosin MP, Cheng X, Poh C, Lam WL, Huang Y, Lovas J, et al. Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. Clin Cancer Res 2000; 6(2):357-62.
  16. Paliga A, Mai KT. Squamous cell carcinomas of the anterior oral cavity are commonly associated with simplex (or differentiated) oral intraepithelial neoplasia: clinical and pathologic significance. Int J Surg Pathol 2014;22(3):231-40.
  17. Kramer IR, Lucas RB, Pindborg JJ, Sobin LH. Definition of leukoplakia and related lesions: an aid to studies on oral precancer. Oral Surg Oral Med Oral Pathol 1978;46(4):518-39.
  18. Agbor MA, Azodo CC, Tefouet TS. Smokeless tobacco use, tooth loss and oral health issues among adults in Cameroon. Afr Health Sci 2013;13(3):785-90.
  19. Neville BW, Day TA. Oral cancer and precancerous lesions. CA Cancer J Clin 2002;52(4):195-215.
  20. Waldron CA, Shafer WG. Leukoplakia revisited. A clinicopathologic study 3256 oral leukoplakias. Cancer 1975;36(4):1386-92.
  21. Pogrel MA. Sublingual keratosis and malignant transformation. J Oral Pathol 1979;8(3):176-8.
  22. Kramer IR, El-Labban N, Lee KW. The clinical features and risk of malignant transformation in sublingual keratosis. Br Dent J 1978;144(6):171-80.
  23. Cowan CG, Gregg TA, Napier SS, McKenna SM, Kee F. Potentially malignant oral lesions in northern Ireland: a 20-year population-based perspective of malignant transformation. Oral Dis 2001;7(1):18-24.
  24. Pindborg JJ, Renstrup G, Poulsen HE, Silverman S Jr. Studies In Oral Leukoplakias. V. Clinical and Histologic Signs of Malignancy. Acta Odontol Scand 1963;21:407-14.
  25. Banoczy J. Follow-up studies in oral leukoplakia. J Maxillofac Surg 1977;5(1):69-75.
  26. Lippman SM, Shin DM, Lee JJ, Batsakis JG, Lotan R, Tainsky MA, Hittleman WN, Hong WK. p53 and retinoid chemoprevention of oral carcinogenesis. Cancer Res 1995;55(1):16-9.
  27. Graveland AP, Bremmer JF, de Maaker M, Brink A, Cobussen P, Zwart M, Braakhuis BJ, Bloemena E,van der Waal I, et al.. Molecular screening of oral precancer. Oral Oncol 2013;49(12):1129-35.
  28. Cui JJ, Han XL, Wang WM. Expression and significance of p53 and mdm2 in patients with leukoplakia cancer. Asian Pac J Trop Med 2013;6(10):831-4.
  29. Xia RH, Song XM, Wang XJ, Li J, Mao L. The combination of SMAD4 expression and histological grade of dysplasia is a better predictor for the malignant transformation of oral leukoplakia. PloS One 2013;8(6):e66794.
  30. Ramasubramanian A, Ramani P, Sherlin HJ, Premkumar P, Natesan A, Thiruvengadam C. Immunohistochemical evaluation of oral epithelial dysplasia using cyclin-D1, p27 and p63 expression as predictors of malignant transformation. J Nat Sci  Biol Med 2013;4(2):349-58.
  31. Jordan RC, Macabeo-Ong M, Shiboski CH, Dekker N, Ginzinger DG, Wong DT, et al. Overexpression of matrix metalloproteinase-1 and -9 mRNA is associated with progression of oral dysplasia to cancer. Clin Cancer Res 2004;10(19):6460-5.
  32. Arora S, Kaur J, Sharma C, Mathur M, Bahadur S, Shukla NK, et al. Stromelysin 3, Ets-1, and vascular endothelial growth factor expression in oral precancerous and cancerous lesions: correlation with microvessel density, progression, and prognosis. Clin Cancer Res 2005;11(6):2272-84.
  33. Luzar B, Poljak M, Marin IJ, Eberlinc A, Klopcic U, Gale N. Human telomerase catalytic subunit gene re-expression is an early event in oral carcinogenesis. Histopathology 2004;45(1):13-9.
  34. Thomas S, Balan A, Balaram P. The expression of retinoblastoma tumor suppressor protein in oral cancers and precancers: A clinicopathological study. Dent Res J 2015;12(4):307-14.
  35. Sinanoglu A, Soluk-Tekkesin M, Olgac V. Cyclooxygenase-2 and Ki67 Expression in Oral Leukoplakia: a Clinicopathological Study. J Oral Maxillofac Res 2015;6(2):e3.
  36. Shafer WG, Waldron CA. A clinical and histopathologic study of oral leukoplakia. Surg Gynecol Obstet 1961;112:411-20.
  37. Bouquot JE, Whitaker SB. Oral leukoplakia--rationale for diagnosis and prognosis of its clinical subtypes or "phases". Quintessence Int 1994;25(2):133-40.
  38. Schepman KP, van der Meij EH, Smeele LE, van der Waal I. Malignant transformation of oral leukoplakia: a follow-up study of a hospital-based population of 166 patients with oral leukoplakia from The Netherlands. Oral Oncol 1998;34(4):270-5.
  39. Shopper TP, Brannon RB, Stalker WH. Proliferative verrucous leukoplakia: an aggressive form of oral leukoplakia. J Dent Hyg 2004;78(3):7.
  40. Summerlin DJ. Precancerous and cancerous lesions of the oral cavity. Dermatol Clin 1996;14(2):205-23.
  41. Hansen LS, Olson JA, Silverman S Jr. Proliferative verrucous leukoplakia. A long-term study of thirty patients. Oral Surg Oral Med Oral Pathol 1985;60(3):285-98.
  42. Bagan J, Scully C, Jimenez Y, Martorell M. Proliferative verrucous leukoplakia: a concise update. Oral Dis 2010;16(4):328-32.
  43. Neville B, Dam D, Allen C, Bouquot J. Oral and Maxillofacial Pathology. 3rd ed. China: Saunders Elsevier; 2009.
  44. Barnes L EJ, Reichart P, Sidransky D. World Health Organization Classification of Tumours.Pathology and Genetics of Head and Neck Tumours. Lyon: IARC Press; 2005.
  45. Qin GZ, Park JY, Chen SY, Lazarus P. A high prevalence of p53 mutations in pre-malignant oral erythroplakia. Int J Cancer 1999;80(3):345-8.
  46. Shafer WG, Waldron CA. Erythroplakia of the oral cavity. Cancer 1975;36(3):1021-8.
  47. Wang YP, Chen HM, Kuo RC, Yu CH, Sun A, Liu BY, et al. Oral verrucous hyperplasia: histologic classification, prognosis, and clinical implications. J Oral Pathol Med 2009;38(8):651-6.
  48. Hazarey VK, Ganvir SM, Bodhade AS. Verrucous hyperplasia: A clinico-pathological study.  J Oral Maxillofac Pathol 2011;15(2):187-91.
  49. Hsue SS, Wang WC, Chen CH, Lin CC, Chen YK, Lin LM. Malignant transformation in 1458 patients with potentially malignant oral mucosal disorders: a follow-up study based in a Taiwanese hospital. J Oral Pathol Med 2007;36(1):25-9.
  50. Shear M, Pindborg JJ. Verrucous hyperplasia of the oral mucosa. Cancer 1980;46(8):1855-62.
  51. Woolgar JA, Triantafyllou A. Squamous cell carcinoma and precursor lesions: clinical pathology. Periodontol 2000 2011;57(1):51-72.
  52. Somatunga LC, Sinha DN, Sumanasekera P, Galapatti K, Rinchen S, Kahandaliyanage A, et al. Smokeless tobacco use in Sri Lanka. Indian J Cancer 2012;49(4):357-63.
  53. Ortiz GM, Pierce AM, Wilson DF. Palatal changes associated with reverse smoking in Filipino women. Oral Dis 1996;2(3):232-7.
  54. Pindborg JJ, Mehta FS, Gupta PC, Daftary DK, Smith CJ. Reverse smoking in Andhra Pradesh, India: a study of palatal lesions among 10,169 villagers. Br J Cancer 1971;25(1):10-20.
  55. Axell T, Pindborg JJ, Smith CJ, van der Waal I. Oral white lesions with special reference to precancerous and tobacco- related lesions: conclusions of an international symposium held in Uppsala, Sweden, May 18-21 1994. International Collaborative Group on Oral White Lesions. J Oral Pathol Med 1996;25(2):49-54.
  56. Ramulu C, Raju MV, Venkatarathnam G, Reddy CR. Nicotine stomatitis and its relation to carcinoma of the hard palate in reverse smokers of chuttas. J Dent Res 1973;52(4):711-8.
  57. Pindborg JJ. Is submucous fibrosis a precancerous condition in the oral cavity? Int Dental J 1972;22(4):474-80.
  58. Tilakaratne WM, Klinikowski MF, Saku T, Peters TJ, Warnakulasuriya S. Oral submucous fibrosis: review on aetiology and pathogenesis. Oral Oncol 2006;42(6):561-8.
  59. Khan I, Kumar N, Pant I, Narra S, Kondaiah P. Activation of TGF-beta pathway by areca nut constituents: a possible cause of oral submucous fibrosis. PloS One 2012;7(12):e51806.
  60. Chaturvedi P, Vaishampayan SS, Nair S, Nair D, Agarwal JP, Kane SV, et al. Oral squamous cell carcinoma arising in background of oral submucous fibrosis: a clinicopathologically distinct disease. Head Neck 2013;35(10):1404-9.
  61. Haque MF, Meghji S, Khitab U, Harris M. Oral submucous fibrosis patients have altered levels of cytokine production. J Oral Pathol Med 2000; 29(3):123-8.
  62. Angadi PV, Rao SS. Areca nut in pathogenesis of oral submucous fibrosis: revisited. Oral Maxillofac Surg 2011;15(1):1-9.
  63. Keshav R, Narayanappa U. Expression of Proliferating Cell Nuclear Antigen (PCNA) in Oral Submucous Fibrosis: An Immunohistochemical Study. J Clin Diagn Res 2015;9 (5):Zc20-3.
  64. Rajalalitha P, Vali S. Molecular pathogenesis of oral submucous fibrosis--a collagen metabolic disorder. J Oral Pathol Med 2005;34(6):321-8.
  65. Kaur J, Rao M, Chakravarti N, Mathur M, Shukla NK, Sanwal BD, et al. Co-expression of colligin and collagen in oral submucous fibrosis: plausible role in pathogenesis. Oral Oncol 2001;37(3):282-7.
  66. Shieh DH, Chiang LC, Shieh TY. Augmented mRNA expression of tissue inhibitor of metalloproteinase-1 in buccal mucosal fibroblasts by arecoline and safrole as a possible pathogenesis for oral submucous fibrosis. Oral Oncol 2003;39(7):728-35.
  67. Ebrahimi M, Nylander K, van der Waal I. Oral lichen planus and the p53 family: what do we know? J Oral Pathol Med 2011;40(4):281-5.
  68. Eversole LR. Immunopathogenesis of oral lichen planus and recurrent aphthous stomatitis. Semin Cutan Med Surg 1997;16(4):284-94.
  69. Holmstrup P. The controversy of a premalignant potential of oral lichen planus is over. Oral Surg Oral Med Oral Pathol 1992;73(6):704-6.
  70. Krutchkoff DJ, Cutler L, Laskowski S. Oral lichen planus: the evidence regarding potential malignant transformation. J Oral Pathol 1978;7(1):1-7.
  71. Krutchkoff DJ, Eisenberg E. Lichenoid dysplasia: a distinct histopathologic entity. Oral Surg Oral Med Oral Pathol 1985;60(3):308-15.
  72. Eisenberg E. Oral lichen planus: a benign lesion. J Oral Maxillofac Surg 2000;58(11):1278-85.
  73. Gandolfo S, Richiardi L, Carrozzo M, Broccoletti R, Carbone M, Pagano M, et al. Risk of oral squamous cell carcinoma in 402 patients with oral lichen planus: a follow-up study in an Italian population. Oral Oncol 2004;40(1):77-83.
  74. Gándara-Reya JM FM, Vilab PG, Carrióna AB, Suárez Peñarandac, Garcia Garciad JMA. Malignant transformation of oral lichen planus in lingual location: report of a case. Oral Oncol Extra 2004;40(1):1-4.
  75. Irani S. Squamous Cell Carcinoma arising in Oral Lichen Planus: A case report. DJH 2010;1(2):1-6.
  76. Fitzpatrick SG, Hirsch SA, Gordon SC. The malignant transformation of oral lichen planus and oral lichenoid lesions: a systematic review. J Am Dent Assoc 2014;145(1):45-56.
  77. Irani S Monsef Esfahani A, Sabeti Sh , Bidari Zerehpoush F. Detection of Helicobacter pylori in Oral Lichen Planus and Oral Lichenoid Reaction. Avicenna J Dent Res 2014;6(2):e23213.
  78. Gonzalez-Moles MA, Scully C. Vesiculo-erosive oral mucosal disease--management with topical corticosteroids: (2) Protocols, monitoring of effects and adverse reactions, and the future. J Dent Res 2005; 84(4):302-8.
  79. Lanfranchi-Tizeira HE, Aguas SC, Sano SM. Malignant transformation of atypical oral lichen planus: a review of 32 cases. Med Oral 2003;8(1):2-9.
  80. Mignogna MD, Lo Muzio L, Lo Russo L, Fedele S, Ruoppo E, Bucci E. Clinical guidelines in early detection of oral squamous cell carcinoma arising in oral lichen planus: a 5-year experience. Oral Oncol 2001;37(3):262-7.
  81. Rajentheran R, McLean NR, Kelly CG, Reed MF, Nolan A. Malignant transformation of oral lichen planus. Eur J Surg Oncol 1999;25(5):520-3.
  82. Mignogna MD, Fedele S, Lo Russo L, Mignogna C, de Rosa G, Porter SR. Field cancerization in oral lichen planus. Eur J Surg Oncol 2007;33(3):383-9.
  83. Coombes D, Cascarini L, Booth PW. Carcinoma of the midline dorsum of the tongue. Br J Oral Maxillofac Surg 2008;46(6):485-6.
  84. Larsson A, Warfvinge G. Malignant transformation of oral lichen planus. Oral Oncol 2003;39(6):630-1.
  85. Gonzalez-Moles MA, Scully C, Gil-Montoya JA. Oral lichen planus: controversies surrounding malignant transformation. Oral Dis 2008;14(3):229-43.
  86. Irani S, Salajegheh A, Smith RA, Lam AK. A review of the profile of endothelin axis in cancer and its management. Crit Rev Oncol/ Hematol 2014;89(2):314-21.
  87. Irani S, Salajegheh A, Gopalan V, Smith RA, Lam AK. Expression profile of endothelin 1 and its receptor endothelin receptor A in papillary thyroid carcinoma and their correlations with clinicopathologic characteristics. Ann Diagn Pathol 2014;18(2):43-8.
  88. Mignogna MD, Fedele S, Lo Russo L, Lo Muzio L, Bucci E. Immune activation and chronic inflammation as the cause of malignancy in oral lichen planus: is there any evidence ? Oral Oncol 2004;40(2):120-30.
  89. Taniguchi Y, Nagao T, Maeda H, Kameyama Y, Warnakulasuriya KA. Epithelial cell proliferation in oral lichen planus. Cell Prolif 2002;35 Suppl 1:103-9.
  90. Ebrahimi M, Boldrup L, Wahlin YB, Coates PJ, Nylander K. Decreased expression of the p63 related proteins beta-catenin, E-cadherin and EGFR in oral lichen planus. Oral Oncol 2008;44(7):634-8.
  91. Nomura H, Uzawa K, Yamano Y, Fushimi K, Nakashima D, Kouzu Y, et al. Down-regulation of plasma membranous Annexin A1 protein expression in premalignant and malignant lesions of the oral cavity: correlation with epithelial differentiation. J Cancer Res Clin Oncol 2009;135(7):943-9.
  92. van der Waal I. Oral lichen planus and oral lichenoid lesions; a critical appraisal with emphasis on the diagnostic aspects. Med Oral Patol Oral Cir Bucal 2009;14(7):E310-4.
  93. Ismail SB, Kumar SK, Zain RB. Oral lichen planus and lichenoid reactions: etiopathogenesis, diagnosis, management and malignant transformation. J Oral Sci 2007;49(2):89-106.
  94. Acay RR, Felizzola CR, de Araujo N, de Sousa SO. Evaluation of proliferative potential in oral lichen planus and oral lichenoid lesions using immunohistochemical expression of p53 and Ki67. Oral Oncol 2006;42(5):475-80.
  95. Muller S. Oral manifestations of dermatologic disease: a focus on lichenoid lesions. Head Neck Pathol 2011;5(1):36-40.
  96. Hiremath SK, Kale AD, Charantimath S. Oral lichenoid lesions: Clinico-pathological mimicry and its diagnostic implications. Indian J Dent Res 2011(22.6):827.
  97. Fine JD, Johnson LB, Weiner M, Li KP, Suchindran C. Epidermolysis bullosa and the risk of life-threatening cancers: the National EB Registry experience, 1986-2006. J Am Acad Dermatol 2009;60(2):203-11.
  98. Fine JD, Eady RA, Bauer EA, Bauer JW, Bruckner-Tuderman L, Heagerty A, et al. The classification of inherited epidermolysis bullosa (EB): Report of the Third International Consensus Meeting on Diagnosis and Classification of EB. J Am Acad Dermatol 2008;58(6):931-50.
  99. Sawamura D, Nakano H, Matsuzaki Y. Overview of epidermolysis bullosa. J Dermatol 2010;37(3):214-9.
  100. Reichart PA. Oral precancerous conditions--an overview. Mund Kiefer  Gesichtschir  2003;7(4):201-7.
  101. Wright JT, Fine JD, Johnson LB. Oral soft tissues in hereditary epidermolysis bullosa. Oral Surg Oral Med Oral Pathol 1991;71(4):440-6.
  102. Martinez L, Goodman P, Crow WN. Squamous cell carcinoma of the maxillary sinus and palate in epidermolysis bullosa: CT demonstration. J Comput Assist Tomogr 1992;16(2):317-9.
  103. Gupta U, Barman KD, Saify K. Squamous cell carcinoma complicating an untreated chronic discoid lupus erythematosus (CDLE) lesion in a black female. J Dermatol 2005;32(12):1010-3.
  104. Aviles Izquierdo JA, Cano Martinez N, Lazaro Ochaita P. Epidemiological characteristics of patients with cutaneous lupus erythematosus. Actas Dermosifiliogra 2014;105(1):69-73.
  105. Schiodt M, Andersen L, Shear M, Smith CJ. Leukoplakia-like lesions developing in patients with oral discoid lupus erythematosus. Acta Odontol Scand 1981; 39 (4):209-16.
  106. Nelson ND, Bertuch AA. Dyskeratosis congenita as a disorder of telomere maintenance. Mutat Res 2012; 730(1-2):43-51.
  107. Dokal I. Dyskeratosis congenita. Hematology Am Soc Hematol Educ Program 2011;2011:480-6.
  108. Vulliamy T, Marrone A, Goldman F, Dearlove A, Bessler M, Mason PJ, et al. The RNA component of telomerase is mutated in autosomal dominant dyskeratosis congenita. Nature 2001;413(6854):432-5.
  109. Holman JD, Dyer JA. Genodermatoses with malignant potential. Curr Opin Pediatr 2007;19(4):446-54.
  110. Ogden GR, Lane DP, Chisholm DM. p53 expression in dyskeratosis congenita: a marker for oral premalignancy? J Clin Pathol 1993;46(2):169-70.
  111. Cavalcante AS, Anbinder AL, Carvalho YR. Actinic cheilitis: clinical and histological features. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons. 2008;66(3):498-503.
  112. Vieira RA, Minicucci EM, Marques ME, Marques SA. Actinic cheilitis and squamous cell carcinoma of the lip: clinical, histopathological and immunogenetic aspects. An Bras Dermatol 2012;87(1):105-14.
  113. Moy RL. Clinical presentation of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol 2000;42(1 Pt 2):8-10.
  114. Souza Freitas V, de Andrade Santos PP, de Almeida Freitas R, Pereira Pinto L, de Souza LB. Mast cells and matrix metalloproteinase 9 expression in actinic cheilitis and lip squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011;112(3):342-8.
  115. Grimbaldeston MA, Skov L, Finlay-Jones JJ, Hart PH. Increased dermal mast cell prevalence and susceptibility to development of basal cell carcinoma in humans. Methods 2002;28(1):90-6.
  116. Gulubova MV. Structural examination of tryptase- and chymase-positive mast cells in livers, containing metastases from gastrointestinal cancers. Clin Exp Metastasis 2003;20(7):611-20.
  117. Araujo CP, Gurgel CA, Ramos EA, Freitas VS, Barbosa Ade A, Jr., Ramalho LM, et al. Accumulation of CD1a-positive Langerhans cells and mast cells in actinic cheilitis. J Mol Histol 2010;41(6):357-65.
  118. Rigel DS, Stein Gold LF. The importance of early diagnosis and treatment of actinic keratosis. J  Am Acad Dermatol 2013;68(1 Suppl 1):S20-7.
  119. Rossi R, Mori M, Lotti T. Actinic keratosis. Int J Dermatol. 2007;46(9):895-904.
  120. Lalji A KN, Lalji M. Actinic keratosis and Squamous Cell Carcinoma. Clin Res Dermatol Open 2014;1(1):1-3.
  121. Marks R, Ponsford MW, Selwood TS, Goodman G, Mason G. Non-melanotic skin cancer and solar keratoses in Victoria. Med J Aust 1983;2(12):619-22.
  122. Bagan JV, Jimenez-Soriano Y, Diaz-Fernandez JM, Murillo-Cortes J, Sanchis-Bielsa JM, Poveda-Roda R, et al. Malignant transformation of proliferative verrucous leukoplakia to oral squamous cell carcinoma: a series of 55 cases. Oral oncology. 2011;47(8):732-5.
  123. Fuchs A, Marmur E. The kinetics of skin cancer: progression of actinic keratosis to squamous cell carcinoma. Dermatol Surg 2007;33(9):1099-101.
  124. Smoller BR. Squamous cell carcinoma: from precursor lesions to high-risk variants. Mod Pathol 2006;19 Suppl 2:S88-92.
  125. Choi KH, Kim GM, Kim SY. The keratin-14 expression in actinic keratosis and squamous cell carcinoma: is this a prognostic factor for tumor progression? Cancer Res Treat 2010;42(2):107-14.
  126. Grimbaldeston MA, Finlay-Jones JJ, Hart PH. Mast cells in photodamaged skin: what is their role in skin cancer? Photoch Photobiol Sci 2006;5(2):177-83.
  127. Kim MS, Kim YK, Lee DH, Seo JE, Cho KH, Eun HC, et al. Acute exposure of human skin to ultraviolet or infrared radiation or heat stimuli increases mast cell numbers and tryptase expression in human skin in vivo. Br J Dermatol 2009;160(2):393-402.
  128. Berhane T, Halliday GM, Cooke B, Barnetson RS. Inflammation is associated with progression of actinic keratoses to squamous cell carcinomas in humans. Br J Dermatol 2002;146(5):810-5.
  129. Chopra V, Tyring SK, Johnson L, Fine JD. Patients with severe forms of inherited epidermolysis bullosa exhibit decreased lymphokine and monokine production. J Clin Immunol 1990;10(6):321-9.
  130. Arbiser JL, Fan CY, Su X, Van Emburgh BO, Cerimele F, Miller MS, et al. Involvement of p53 and p16 tumor suppressor genes in recessive dystrophic epidermolysis bullosa-associated squamous cell carcinoma. J Invest Dermatol 2004;123(4):788-90.
  131. Dang N, Murrell DF. Mutation analysis and characterization of COL7A1 mutations in dystrophic epidermolysis bullosa. Exp Dermatol 2008;17(7):553-68.
  132. 132.Bauer JW, Schaeppi H, Kaserer C, Hantich B, Hintner H. Large melanocytic nevi in hereditary epidermolysis bullosa. J Am Acad Dermatol 2001;44(4):577-84.
  133. Pellicano R, Fabrizi G, Cerimele D. Multiple keratoacanthomas and junctional epidermolysis bullosa. A therapeutic conundrum. Arch Dermatol 1990;126(3):305-6.
  134. Weber F, Bauer JW, Sepp N, Hogler W, Salmhofer W, Hintner H, et al. Squamous cell carcinoma in junctional and dystrophic epidermolysis bullosa. Acta Derm Venereol 2001;81(3):189-92.
  135. 135.Millard LG, Barker DJ. Development of squamous cell carcinoma in chronic discoid lupus erythematosus. Clin Exp Dermatol 1978;3(2):161-6.
  136. Harper JG, Pilcher MF, Szlam S, Lind DS. Squamous cell carcinoma in an African American with discoid lupus erythematosus: a case report and review of the literature. South Med J 2010;103(3):256-9.
  137. Greenberg MS GM. Burket’s oral medicine. Diagnosis and Treatment. 10th ed. Philadelphia: Lippincott Company; 2003.
  138. Bhat MR, Hulmani M, Dandakeri S, Kambil SM, Gatti R. Disseminated discoid lupus erythematosus leading to squamous cell carcinoma. Indian J Dermatol 2012;57(2):158-61.
  139. Copcu E, Aktas A, Sisman N, Oztan Y. Thirty-one cases of Marjolin's ulcer. Clin Exp Dermatol 2003;28(2):138-41.
  140. Mallipeddi R, Keane FM, McGrath JA, Mayou BJ, Eady RA. Increased risk of squamous cell carcinoma in junctional epidermolysis bullosa. J Eur Acad Dermatol Venerol 2004;18(5):521-6.
  141. Schiodt M. Oral discoid lupus erythematosus. III. A histopathologic study of sixty-six patients. Oral Surg Oral Med Oral Pathol 1984;57(3):281-93.
  142. 142.Atkinson JC, Harvey KE, Domingo DL, Trujillo MI, Guadagnini JP, Gollins S, et al. Oral and dental phenotype of dyskeratosis congenita. Oral Dis 2008;14(5):419-27.
  143. Salopek TG, Kopf AW, Stefanato CM, Vossaert K, Silverman M, Yadav S. Differentiation of atypical moles (dysplastic nevi) from early melanomas by dermoscopy. Dermatol Clin 2001;19(2):337-45.
  144. Goldstein AM, Struewing JP, Chidambaram A, Fraser MC, Tucker MA. Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations. J Nati Cancer Inst 2000;92(12):1006-10.
  145. Farber MJ, Heilman ER, Friedman RJ. Dysplastic nevi. Dermatol Clin 2012;30(3):389-404.
  146. Elder DE. Dysplastic naevi: an update. Histopathology 2010;56(1):112-20.
  147. de Wit PE, van't Hof-Grootenboer B, Ruiter DJ, Bondi R, Brocker EB, Cesarini JP, et al. Validity of the histopathological criteria used for diagnosing dysplastic naevi. An interobserver study by the pathology subgroup of the EORTC Malignant Melanoma Cooperative Group. Eur  J Cancer 1993;29a(6):831-9.
  148. Lyon VB. Congenital melanocytic nevi. Pediatr Clin North Am 2010;57(5):1155-76.
  149. Boente Mdel C, Asial RA. Desmoplastic hairless hypopigmented nevus (DHHN). A distinct variant of giant melanocytic nevus. Eur J Dermatol 2005;15(6):451-3.
  150. Gozel S, Donmez M, Akdur NC, Yikilkan H. Development of six tumors in a sebaceus nevus of jadassohn: report of a case. Korean J Pathol 2013;47(6):569-74.
  151. Lanssens S, Ongenae K. Dermatologic lesions and risk for cancer. Acta Clin Belg 2011;66(3):177-85.
  152. Califano J, van der Riet P, Westra W, Nawroz H, Clayman G, Piantadosi S, et al. Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res 1996;56(11):2488-92.
  153. 153.Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 1953;6(5):963-8.
  154. Gotti C, Clementi F. Neuronal nicotinic receptors: from structure to pathology. Prog Neurobiol 2004;74(6):363-96.
  155. Zeidler R, Albermann K, Lang S. Nicotine and apoptosis. Apoptosis 2007;12(11):1927-43.
  156. Arora S, Aggarwal P, Pathak A, Bhandari R, Duffoo F, Gulati SC. Molecular genetics of head and neck cancer (Review). Mol Med Rep 2012;6(1):19-22.
  157. 157.Gainza-Cirauqui ML, Nieminen MT, Novak Frazer L, Aguirre-Urizar JM, Moragues MD, Rautemaa R. Production of carcinogenic acetaldehyde by Candida albicans from patients with potentially malignant oral mucosal disorders. J Oral Pathol Med 2013;42(3):243-9.
  158. Johnson NW, Jayasekara P, Amarasinghe AA. Squamous cell carcinoma and precursor lesions of the oral cavity: epidemiology and aetiology. Periodontol 2000 2011;57(1):19-37.
  159. Chen AC, Halliday GM, Damian DL. Non-melanoma skin cancer: carcinogenesis and chemoprevention. Pathology 2013;45(3):331-41.
  160. Salajegheh A, Dolan-Evans E, Sullivan E, Irani S, Rahman MA, Vosgha H, et al. The expression profiles of the galectin gene family in primary and metastatic papillary thyroid carcinoma with particular emphasis on galectin-1 and galectin-3 expression. Exp Mol Pathol 2014;96(2):212-8.
  161. Raica M, Cimpean AM, Ribatti D. Angiogenesis in pre-malignant conditions. Eur J Cancer 2009;45(11):1924-34.
  162. Degen M, Natarajan E, Barron P, Widlund HR, Rheinwald JG. MAPK/ERK-dependent translation factor hyperactivation and dysregulated laminin gamma2 expression in oral dysplasia and squamous cell carcinoma. Am J Pathol  2012;180(6):2462-78.
  163. Nordemar S, Hogmo A, Lindholm J, Auer G, Munck-Wikland E. Laminin-5 gamma 2: a marker to identify oral mucosal lesions at risk for tumor development? Anticancer Res 2003;23(6d):4985-9.
  164. Inoue H, Miyazaki Y, Kikuchi K, Yoshida N, Ide F, Ohmori Y, et al. Podoplanin expression during dysplasia-carcinoma sequence in the oral cavity. Tumour Biol. 2012;33(1):183-94.
Iranian Journal of Pathology
Volume 11, Issue 4
October 2016
Pages 303-322
Files
History
  • Receive Date: 03 October 2015
  • Revise Date: 02 April 2016
  • Accept Date: 04 April 2016
Share
How to cite
Statistics